

---

# 5.90.19

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2021
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 29, 2016
<b>Subject:</b>	Aldara	<b>Page:</b>	1 of 5

---

**Last Review Date:** March 12, 2021

---

## Aldara

### Description

#### Aldara (imiquimod)

#### Background

Aldara (imiquimod) cream is used for the treatment of actinic keratosis (AK), external genital and perianal warts, and primary superficial basal cell carcinoma (sBCC). Actinic keratosis (AK), also called solar keratosis, which is a chronic (long-term) condition of the skin caused by a chemical reaction to ultraviolet (UV) rays. Actinic keratosis (AK) can be linked to the development of skin cancer. Superficial basal cell carcinoma (sBCC) is the most common form of skin cancer. It usually develops on skin that gets the most sun exposure such as on the backs of hands, on the head, and neck. External genital and perianal warts, also called condyloma acuminata (EGW), are caused by a virus known as human papillomavirus (HPV), and spread through sexual contact. Genital warts rarely cause health problems, but local symptoms of pain and itching may occur (1).

#### Regulatory Status

FDA-approved indication: Aldara cream is indicated for the topical treatment of: (1)

1. Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults.
2. Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.
3. External genital and perianal warts/condyloma acuminata in patients 12 years old or older

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2021
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 29, 2016
<b>Subject:</b>	Aldara	<b>Page:</b>	2 of 5

---

Warning and precautions that should be discussed with the patient on Aldara therapy include intense local inflammatory reactions at application site which can lead to severe vulvar swelling. Severe vulvar swelling can lead to urinary retention (1).

### Related policies

Klisyri, Solaraze, Zyclara

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Aldara may be considered **medically necessary** in patients 18 years of age or older with actinic keratosis and if the conditions indicated below are met.

Aldara may be considered **medically necessary** in patients 12 years of age or older with external genital and perianal warts and if the conditions indicated below are met.

Aldara may be considered **medically necessary** in patients 18 years of age or older with superficial basal cell carcinoma (sBCC) and if the conditions indicated below are met.

Aldara may be considered **investigational** in patients with all other indications.

## Prior-Approval Requirements

### Diagnoses

Patient must have **ONE** the following:

1. Actinic keratosis (AK)
  - a. 18 years of age or older
  - b. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following topical formulations:
    - i. Generic imiquimod
    - ii. Fluorouracil
    - iii. Diclofenac
2. External genital and perianal warts (EGW)
  - a. 12 years of age or older

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2021
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 29, 2016
<b>Subject:</b>	Aldara	<b>Page:</b>	3 of 5

---

- b. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following topical formulations:
  - i. Generic imiquimod
  - ii. Podofilox
  - iii. Fluorouracil
  - iv. Trichloroacetic acid
  
- 3. Superficial basal cell carcinoma (sBCC)
  - a. 18 years of age or older
  - b. Biopsy-confirmed with a maximum tumor diameter of 2.0 cm.
  - c. **NOT** for treatment on head, hands, feet, and anogenital skin
  - d. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following:
    - i. Generic imiquimod
    - ii. Mohs surgery
    - iii. Surgical excision
    - iv. Radiation

## Prior – Approval *Renewal* Requirements

### Diagnoses

Patient must have **ONE** the following:

- 1. Actinic keratosis (AK)
  - a. 18 years of age or older
- 2. External genital and perianal warts (EGW)
  - a. 12 years of age or older
- 3. Superficial basal cell carcinoma (sBCC)
  - a. 18 years of age or older

**AND ALL** of the following:

Re-evaluation of lesion(s) / warts for improvement

### [Policy Guidelines](#)

### Pre - PA Allowance

None

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2021
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 29, 2016
<b>Subject:</b>	Aldara	<b>Page:</b>	4 of 5

### Prior - Approval Limits

**Quantity** 5% Packets 48 (2 boxes)

**Duration** 3 month

### Prior – Approval *Renewal* Limits

**Quantity** 5% Packets 48 (2 boxes)

**Duration** 3 month (One renewal only)

### Rationale

#### Summary

Aldara (imiquimod) cream is a prescription medicine used on the skin for actinic keratosis (AK), external genital and perianal warts, and superficial basal cell carcinoma (sBCC). Actinic keratosis (AK) is a chronic (long-term) condition of the skin and can be linked to the development of skin cancer. Superficial basal cell carcinoma (sBCC) is cancer of the skin caused by excessive sun exposure. External genital and perianal warts, also called condyloma acuminata (EGW), are caused by a virus known as human papillomavirus (HPV), and spread through sexual contact. Genital warts rarely cause health problems, but local symptoms of pain and itching may occur (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Aldara while maintaining optimal therapeutic outcomes.

#### References

1. Aldara [package Insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC.; April 2018.

### Policy History

Date	Action
April 2016	Addition to PA
June 2016	Annual review
December 2016	Annual editorial review Addition age requirements to renewal criteria
March 2017	Annual review
September 2018	Annual review and reference update

# 5.90.19

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2021
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 29, 2016
<b>Subject:</b>	Aldara	<b>Page:</b>	5 of 5

---

September 2019    Annual review and reference update  
September 2020    Annual review  
March 2021        Annual editorial review

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 12, 2021 and is effective on April 1, 2021.**